On October 27, 2021 Adhera Therapeutics, Inc. (the "Company") reported that an institutional investor who holds two convertible promissory notes (the "Notes") agreed to extend the maturity date of each of the Notes by six months (Filing, 8-K, Adhera Therapeutics, OCT 27, 2021, View Source [SID1234592025]). The $220,500 Note issued in August 2021 had its maturity date extended to February 17, 2023 and the $66,500 Note issued in June 2021 had its maturity date extended to December 25, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!